ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2026
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.
Matthias Augustin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it